We are live on ! Find out more
PHP

Parkman Healthcare Partners Portfolio holdings

AUM $970M
1-Year Est. Return 79.46%
This Fund
S&P 500
This Quarter Est. Return
+2.74%
1 Year Est. Return
+79.46%
3 Year Est. Return
+312.89%
5 Year Est. Return
+648.59%
10 Year Est. Return
–
AUM
$747M
AUM Growth
-$68.4M
Cap. Flow
-$45M
Cap. Flow %
-6.03%
Top 10 Hldgs %
35.25%
Holding
111
New
12
Increased
44
Reduced
34
Closed
21

Top Buys

Rank Stock Value
1
AGIO icon
Agios Pharmaceuticals
AGIO
+$16.1M
2
PODD icon
Insulet
PODD
+$15.9M
3
ICLR icon
Icon
ICLR
+$11.6M
4
HUM icon
Humana
HUM
+$10.1M
5
BSX icon
Boston Scientific
BSX
+$9.23M

Top Sells

Rank Stock Value
1
INSP icon
Inspire Medical Systems
INSP
+$17.4M
2
THC icon
Tenet Healthcare
THC
+$16.2M
3
SILK
Silk Road Medical, Inc. Common Stock
SILK
+$15.6M
4
COR icon
Cencora
COR
+$13.9M
5
OSCR icon
Oscar Health
OSCR
+$12.4M

Sector Composition

Rank Sector Weight
1 Healthcare 98.27%
2 Industrials 0.07%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EWTX icon
26
Edgewise Therapeutics
EWTX
$4.84B
$10.3M 1.39%
574,517
-79,136
-12% -$1.38M
NRIX icon
27
Nurix Therapeutics
NRIX
$2.74B
$9.91M 1.33%
474,679
+224,679
+90% +$3.5M
QGEN icon
28
Qiagen
QGEN
$8.84B
$9.63M 1.29%
227,760
-77,473
-25% -$3.4M
NARI
29
DELISTED
Inari Medical, Inc. Common Stock
NARI
$9.42M 1.26%
195,567
+70,229
+56% +$3.11M
KROS icon
30
Keros Therapeutics
KROS
$212M
$9.08M 1.22%
198,627
+20,292
+11% +$1.09M
ATEC icon
31
Alphatec Holdings
ATEC
$1.43B
$8.91M 1.19%
852,416
+515,728
+153% +$6M
ACLX
32
DELISTED
Arcellx
ACLX
$8.66M 1.16%
156,843
+245
+0.2% +$13.3K
VRNA
33
DELISTED
Verona Pharma
VRNA
$8.61M 1.15%
595,389
+65,869
+12% +$962K
GILD icon
34
Gilead Sciences
GILD
$170B
$8.58M 1.15%
+125,000
New +$8.34M
COR icon
35
Cencora
COR
$61.4B
$8.56M 1.15%
38,014
-59,891
-61% -$13.9M
BMY icon
36
Bristol-Myers Squibb
BMY
$131B
$8.31M 1.11%
+200,000
New +$8.95M
XENE icon
37
Xenon Pharmaceuticals
XENE
$6.23B
$8.16M 1.09%
209,290
-14,652
-7% -$586K
TVTX icon
38
Travere Therapeutics
TVTX
$5.86B
$7.97M 1.07%
969,892
+1,472
+0.2% +$9.91K
IONS icon
39
Ionis Pharmaceuticals
IONS
$9.4B
$7.71M 1.03%
161,705
+20,206
+14% +$829K
ANAB icon
40
AnaptysBio
ANAB
$1.71B
$6.42M 0.86%
+256,307
New +$5.97M
CRNX icon
41
Crinetics Pharmaceuticals
CRNX
$8.96B
$6.33M 0.85%
141,375
+40,256
+40% +$1.86M
RCUS icon
42
Arcus Biosciences
RCUS
$3.71B
$6.33M 0.85%
415,535
+155,615
+60% +$2.51M
HAE icon
43
Haemonetics
HAE
$4.06B
$6.29M 0.84%
76,079
-14,883
-16% -$1.31M
CSTL icon
44
Castle Biosciences
CSTL
$986M
$6.05M 0.81%
277,895
-89,513
-24% -$1.99M
TEVA icon
45
Teva Pharmaceuticals
TEVA
$42.7B
$5.75M 0.77%
353,942
-99,648
-22% -$1.53M
IRWD icon
46
Ironwood Pharmaceuticals
IRWD
$732M
$5.71M 0.77%
876,268
+26,268
+3% +$186K
SLN
47
Silence Therapeutics
SLN
$686M
$5.51M 0.74%
289,841
+45,370
+19% +$965K
INSM icon
48
Insmed
INSM
$29.3B
$5.38M 0.72%
80,271
-12,761
-14% -$495K
CVRX icon
49
CVRx
CVRX
$68.5M
$5.37M 0.72%
447,620
+115,530
+35% +$1.33M
APLT
50
DELISTED
Applied Therapeutics
APLT
$5.36M 0.72%
1,148,307
-706,456
-38% -$3.34M
1
2
3 4 5

Similar funds

LOIM
Liberty One Investment Management Libertyville, Illinois $970M AUM 12.15% 1-Year Est. Return
MGCM
Mane Global Capital Management New York $971M AUM 58.5% 1-Year Est. Return
JWM
Jackson Wealth Management Lake Mary, Florida $972M AUM 22.58% 1-Year Est. Return
WAM
WNY Asset Management Williamsville, New York $967M AUM
GHC
Graham Holdings Company Arlington, Virginia $967M AUM 15.12% 1-Year Est. Return
SAM
Stansberry Asset Management Westlake, Texas $973M AUM 21.39% 1-Year Est. Return
TCCM
Two Creeks Capital Management New York $974M AUM 2.54% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return

Parkman Healthcare Partners's Q2 2024 Portfolio in Review

As of Q2 2024, Parkman Healthcare Partners held 111 positions worth $747M, down 8.4% from $815M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Parkman Healthcare Partners withdrew a net $45M in Q2 2024, closing 21 positions and reducing 34 holdings. Its most notable exit was Inspire Medical Systems, an estimated $17.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Industrials.

Against the trend, Parkman Healthcare Partners opened a new position in Agios Pharmaceuticals worth $19.2M.

  • Parkman Healthcare Partners's largest Q2 2024 buy was Agios Pharmaceuticals: 446,416 shares worth $19.2M.
  • Parkman Healthcare Partners added most to Insulet in Q2 2024, an estimated $15.9M increase.
  • Parkman Healthcare Partners's biggest Q2 2024 reduction was Tenet Healthcare, cutting an estimated $16.2M.
  • Parkman Healthcare Partners fully exited Inspire Medical Systems in Q2 2024, selling an estimated $17.4M.
  • Parkman Healthcare Partners's ten largest holdings make up 35% of its $747M portfolio in Q2 2024.
  • Parkman Healthcare Partners opened 12 new positions and closed 21 in Q2 2024.
  • Parkman Healthcare Partners's portfolio value fell 8.4% quarter-over-quarter to $747M.

Based on Parkman Healthcare Partners's 13F filing for Q2 2024, filed 14 Aug 2024.